Compare AbbVie Inc (ABBV) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs PulteGroup, Inc. — how do they compare? AbbVie Inc trades at $247.28 (market cap $441.94B), while PulteGroup, Inc. trades at $129.68 (market cap $25.22B). The key difference: AbbVie Inc is far larger — about 17.5× PulteGroup, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | PHM | |
|---|---|---|
Market Cap | $441.94B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $142.56 |
52-Week Low | $197.38 | $110.11 |
Enterprise Value | $506.19B | $25.64B |
Dividend Yield | 2.77% | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
PulteGroup (PHM) trades at $129.72, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.20. The company reported Q2 2026 earnings of $2.48 per share, beating estimates, but revenue and margins have softened amid housing market pressures. Recent news highlights operational expansion into Northwest Florida and recognition as a Great Place to Work.
The outlook is mixed: strong cash flow, a solid balance sheet, and share buybacks support the stock, but declining net income margins and affordability challenges pose headwinds. With 43% of analysts rating it a buy, the stock offers moderate upside potential balanced against cyclical housing risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
